Table 1.

WASp mutation and expression in patients with XLT and WAS


Patient

Exon

cDNA nucl

Mutation

Predicted protein

Protein expression

Clinical score
XLT phenotype       
W2   1   150   T>C   L39P   Dec   2  
W3   1   150   T>C   L39P   Dec   2  
W7   2   201   C>T   A56V   Dec   1  
W8   3   348   T>C   L105P   Dec   2  
W10   2   207   C>G   P58R   Dec   1  
W11   2   207   C>G   P58R   Dec   1  
W12   7   741   C>G   A236G   Dec   1  
W18   2   263   G>C   D77H   Dec   2  
W19   11   1476   T>A   I481N   Dec   1  
WAS phenotype       
W4   7   664   del A   fsX261   Und   4  
W5   7   +1 int. 7   G>T   Splicing defect   Und   5  
W9   4   485-486   del AG   fsX168   ND   5  
W13   1   125   G>A   E31K   Und   3  
W15   4   435   C>T   A134V   Und   4  
W22
 
10
 
1115-1119
 
del C
 
P362X445
 
Und
 
4
 

Patient

Exon

cDNA nucl

Mutation

Predicted protein

Protein expression

Clinical score
XLT phenotype       
W2   1   150   T>C   L39P   Dec   2  
W3   1   150   T>C   L39P   Dec   2  
W7   2   201   C>T   A56V   Dec   1  
W8   3   348   T>C   L105P   Dec   2  
W10   2   207   C>G   P58R   Dec   1  
W11   2   207   C>G   P58R   Dec   1  
W12   7   741   C>G   A236G   Dec   1  
W18   2   263   G>C   D77H   Dec   2  
W19   11   1476   T>A   I481N   Dec   1  
WAS phenotype       
W4   7   664   del A   fsX261   Und   4  
W5   7   +1 int. 7   G>T   Splicing defect   Und   5  
W9   4   485-486   del AG   fsX168   ND   5  
W13   1   125   G>A   E31K   Und   3  
W15   4   435   C>T   A134V   Und   4  
W22
 
10
 
1115-1119
 
del C
 
P362X445
 
Und
 
4
 

Mutations of the WASP gene were identified in all patients through SSCP analysis and polymerase chain reaction (PCR) sequencing.

Protein expression was evaluated using Western blot, immunofluorescence, or cytofluorometric analysis. Clinical score was determined in accordance with Zhu et al.17  nucl indicates nucleotide; Dec, decreased; Und, undetectable; ND, not determined; and int, introne.

or Create an Account

Close Modal
Close Modal